Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.

Sasaki T, Gannam ZTK, Kudalkar SN, Frey KM, Lee WG, Spasov KA, Jorgensen WL, Anderson KS.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2182-2188. doi: 10.1016/j.bmcl.2019.06.047. Epub 2019 Jun 26.

PMID:
31281023
2.

A novel learning approach to pharmaceutical sciences research in a pharmacy research advanced pharmacy practice experience (APPE) elective course.

Tetenbaum-Novatt JE, Lonie JM, Elkowitz DE, Frey KM.

Curr Pharm Teach Learn. 2018 Nov;10(11):1529-1540. doi: 10.1016/j.cptl.2018.08.015. Epub 2018 Aug 24.

PMID:
30514546
3.

Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors.

Azeem SM, Muwonge AN, Thakkar N, Lam KW, Frey KM.

J Mol Graph Model. 2018 Jan;79:133-139. doi: 10.1016/j.jmgm.2017.10.023. Epub 2017 Nov 9.

PMID:
29156381
4.

Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.

Frey KM.

Future Microbiol. 2015;10(11):1767-72. doi: 10.2217/fmb.15.122. Epub 2015 Oct 30. Review.

PMID:
26517310
5.

Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.

Gray WT, Frey KM, Laskey SB, Mislak AC, Spasov KA, Lee WG, Bollini M, Siliciano RF, Jorgensen WL, Anderson KS.

ACS Med Chem Lett. 2015 Aug 31;6(10):1075-9. doi: 10.1021/acsmedchemlett.5b00254. eCollection 2015 Oct 8.

6.

Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase.

Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Chan AH, Anderson KS, Jorgensen WL.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4824-4827. doi: 10.1016/j.bmcl.2015.06.074. Epub 2015 Jul 9.

7.

Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.

Frey KM, Puleo DE, Spasov KA, Bollini M, Jorgensen WL, Anderson KS.

J Med Chem. 2015 Mar 26;58(6):2737-45. doi: 10.1021/jm501908a. Epub 2015 Mar 5.

8.

Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.

Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS.

ACS Chem Biol. 2015 May 15;10(5):1319-29. doi: 10.1021/acschembio.5b00014. Epub 2015 Feb 24.

9.

Protein design algorithms predict viable resistance to an experimental antifolate.

Reeve SM, Gainza P, Frey KM, Georgiev I, Donald BR, Anderson AC.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):749-54. doi: 10.1073/pnas.1411548112. Epub 2014 Dec 31.

10.

Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.

Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Bollini M, Anderson KS, Jorgensen WL.

ACS Med Chem Lett. 2014 Oct 13;5(11):1259-62. doi: 10.1021/ml5003713. eCollection 2014 Nov 13.

11.

Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.

Kumar VP, Cisneros JA, Frey KM, Castellanos-Gonzalez A, Wang Y, Gangjee A, White AC Jr, Jorgensen WL, Anderson KS.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4158-61. doi: 10.1016/j.bmcl.2014.07.049. Epub 2014 Jul 24.

12.

Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.

Iyidogan P, Sullivan TJ, Chordia MD, Frey KM, Anderson KS.

ACS Med Chem Lett. 2013 Oct 15;4(12):1183-8. doi: 10.1021/ml4002979. eCollection 2013 Dec 12.

13.

A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.

Mislak AC, Frey KM, Bollini M, Jorgensen WL, Anderson KS.

Biochim Biophys Acta. 2014 Jul;1840(7):2203-11. doi: 10.1016/j.bbagen.2014.04.001. Epub 2014 Apr 12.

14.

Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.

Frey KM, Gray WT, Spasov KA, Bollini M, Gallardo-Macias R, Jorgensen WL, Anderson KS.

Chem Biol Drug Des. 2014 May;83(5):541-9. doi: 10.1111/cbdd.12266. Epub 2014 Mar 14.

15.

Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group.

Lee WG, Gallardo-Macias R, Frey KM, Spasov KA, Bollini M, Anderson KS, Jorgensen WL.

J Am Chem Soc. 2013 Nov 6;135(44):16705-13. doi: 10.1021/ja408917n. Epub 2013 Oct 24.

16.

Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.

Kumar VP, Frey KM, Wang Y, Jain HK, Gangjee A, Anderson KS.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5426-8. doi: 10.1016/j.bmcl.2013.07.037. Epub 2013 Jul 24.

17.

Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.

Bollini M, Frey KM, Cisneros JA, Spasov KA, Das K, Bauman JD, Arnold E, Anderson KS, Jorgensen WL.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5209-12. doi: 10.1016/j.bmcl.2013.06.093. Epub 2013 Jul 8.

18.

Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.

Frey KM, Bollini M, Mislak AC, Cisneros JA, Gallardo-Macias R, Jorgensen WL, Anderson KS.

J Am Chem Soc. 2012 Dec 5;134(48):19501-3. doi: 10.1021/ja3092642. Epub 2012 Nov 19.

19.

Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.

Kim J, Wang L, Li Y, Becnel KD, Frey KM, Garforth SJ, Prasad VR, Schinazi RF, Liotta DC, Anderson KS.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4064-7. doi: 10.1016/j.bmcl.2012.04.078. Epub 2012 Apr 24.

20.

Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance.

Frey KM, Viswanathan K, Wright DL, Anderson AC.

Antimicrob Agents Chemother. 2012 Jul;56(7):3556-62. doi: 10.1128/AAC.06263-11. Epub 2012 Apr 9.

21.

Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes.

Viswanathan K, Frey KM, Scocchera EW, Martin BD, Swain Iii PW, Alverson JB, Priestley ND, Anderson AC, Wright DL.

PLoS One. 2012;7(2):e29434. doi: 10.1371/journal.pone.0029434. Epub 2012 Feb 7.

22.

Predicting resistance mutations using protein design algorithms.

Frey KM, Georgiev I, Donald BR, Anderson AC.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13707-12. doi: 10.1073/pnas.1002162107. Epub 2010 Jul 19.

23.

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.

Frey KM, Lombardo MN, Wright DL, Anderson AC.

J Struct Biol. 2010 Apr;170(1):93-7. doi: 10.1016/j.jsb.2009.12.011. Epub 2009 Dec 21.

24.

The solution structure of Bacillus anthracis dihydrofolate reductase yields insight into the analysis of structure-activity relationships for novel inhibitors.

Beierlein JM, Deshmukh L, Frey KM, Vinogradova O, Anderson AC.

Biochemistry. 2009 May 19;48(19):4100-8. doi: 10.1021/bi802319w.

25.

Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance.

Frey KM, Liu J, Lombardo MN, Bolstad DB, Wright DL, Anderson AC.

J Mol Biol. 2009 Apr 17;387(5):1298-308. doi: 10.1016/j.jmb.2009.02.045. Epub 2009 Feb 26.

26.

Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.

Beierlein JM, Frey KM, Bolstad DB, Pelphrey PM, Joska TM, Smith AE, Priestley ND, Wright DL, Anderson AC.

J Med Chem. 2008 Dec 11;51(23):7532-40. doi: 10.1021/jm800776a.

27.

Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium.

Bolstad DB, Bolstad ES, Frey KM, Wright DL, Anderson AC.

J Med Chem. 2008 Nov 13;51(21):6839-52. doi: 10.1021/jm8009124. Epub 2008 Oct 4.

28.
29.

Technical-scale production of cyanophycin with recombinant strains of Escherichia coli.

Frey KM, Oppermann-Sanio FB, Schmidt H, Steinb├╝chel A.

Appl Environ Microbiol. 2002 Jul;68(7):3377-84.

Supplemental Content

Support Center